NCI COVID-19 in Cancer Patients
NCI COVID-19 in Cancer Patients, or NCCAPS Study
Official Title: NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Disease Type: Cancer - COVID-19
This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
Study Population: Patients with a prior or current cancer diagnosis and with a positive SARS CoV-2 test within 14 days of enrollment
Participants must meet the following criteria:
- Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
- Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) for metastatic cancer. Eligible treatment types are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, or radiation therapy; or
- Patients is receiving adjuvant treatment for non-metastatic (stage I-III) cancer and has received intravenous chemotherapy, immunotherapy, targeted therapy, or radiation therapy within the past 6 weeks; or
- Patient has received an allogenic stem cell transplant or chimeric antigen receptor (CAR)-T cell or other modified cellular therapy at any time; or
- Patient is currently receiving treatment or prophylaxis for graft versus (vs.) host disease; or
- Patient has received an autologous bone marrow transplant within the past 2 years.
- Patient must have a documented positive SARS CoV-2 test. The positive test results must have been received no earlier than 14 days prior to enrollment. The test must have been ordered by a doctor's office, hospital, or department of public health. Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the SARS CoV-2 test.
Of note, patients who have recently received a SARS CoV-2 test may also be eligible to sign consent but will only be enrolled if final test result is positive.
For More Detailed Information, Contact:
Women’s Health Clinical Research Unit, Email: [email protected] or Call: 310-794-9652.